Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
6.10. rezultāts no 100.
45. lappuse
... ingredients . Based on evidence currently available , any OTC drug product offered for the treat- ment of boils cannot ... ingredient sabal have been present in over - the - counter ( OTC ) drug products to relieve the symptoms of benign ...
... ingredients . Based on evidence currently available , any OTC drug product offered for the treat- ment of boils cannot ... ingredient sabal have been present in over - the - counter ( OTC ) drug products to relieve the symptoms of benign ...
46. lappuse
... ingredients offered over - the- counter ( OTC ) for human use as an anticholinergic in cough - cold drug products . ( a ) ... ingredient . The bella- donna alkaloids , which contain atro- pine ( d , dl hyoscyamine ) and scopol- amine ( l ...
... ingredients offered over - the- counter ( OTC ) for human use as an anticholinergic in cough - cold drug products . ( a ) ... ingredient . The bella- donna alkaloids , which contain atro- pine ( d , dl hyoscyamine ) and scopol- amine ( l ...
47. lappuse
... ingredients offered over - the- counter ( OTC ) for use as a nail- biting or thumbsucking deterrent . ( a ) Denatonium benzoate and sucrose octaacetate have been present in OTC nailbiting and thumbsucking deterrent drug products . There ...
... ingredients offered over - the- counter ( OTC ) for use as a nail- biting or thumbsucking deterrent . ( a ) Denatonium benzoate and sucrose octaacetate have been present in OTC nailbiting and thumbsucking deterrent drug products . There ...
48. lappuse
... ingredients in such products . There is lack of ade- quate data to establish general rec- ognition of the safety and effectiveness of these or any other ingredients for OTC use for ingrown toenail relief . Based on evidence currently ...
... ingredients in such products . There is lack of ade- quate data to establish general rec- ognition of the safety and effectiveness of these or any other ingredients for OTC use for ingrown toenail relief . Based on evidence currently ...
49. lappuse
... ingredients offered for OTC use in the treatment of hypophosphatemia cannot be considered generally recog- nized as safe and effective . ( b ) Any drug product that is labeled , represented , or promoted for OTC use in the treatment of ...
... ingredients offered for OTC use in the treatment of hypophosphatemia cannot be considered generally recog- nized as safe and effective . ( b ) Any drug product that is labeled , represented , or promoted for OTC use in the treatment of ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning